Authors: Poon S, Pupco A, Koren G, Bozzo P
Abstract
QUESTION: I have a patient recently confirmed to be 6 weeks pregnant. For the past 6 months she has been treated for an opioid addiction with buprenorphine-naloxone combination. Should I be concerned about her exposure to this drug combination up to this point of the pregnancy? Should I switch her medication to methadone now that she is pregnant?
ANSWER: The limited data on buprenorphine exposure during pregnancy show no increased risk of adverse outcomes in the newborn. There are limited data on naloxone exposure during pregnancy; however, oral use is not expected to be associated with an increased risk of adverse pregnancy outcomes. Physicians treating pregnant women or women who become pregnant while they are stable taking …

Updated Date: Jun 30, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Jun 30, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Orexo AB announced new topline results of 2 clinical trials with a combination of buprenorphine and naloxone for buprenorphine induction and plans to pursue approval of an expanded label in the US. Medscape Medical News (Source: Medscape Medical News Headlines)

Orexo AB announced new topline results of 2 clinical trials with a combination of buprenorphine and naloxone for buprenorphine induction and plans to pursue approval of an expanded label in the US. Medscape Medical News (Source: Medscape Medical News Headlines)

CONCLUSIONS: It is difficult to draft conclusions on the basis of only two trials. One of the possible reasons for the lack of evidence could be the difficulty of conducting trials with young people for practical and ethical reasons.There is an urgent need for further randomised controlled trials comparing maintenance treatment with detoxification treatment or psychosocial treatment alone before carrying out studies that compare different pharmacological maintenance treatments. These studies should have long follow-up and measure relapse rates after the end of treatment and social functioning (integration at school or at work, family relationships).
PMID: 24957634 [PubMed – as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)

(Source: RxList – New and Updated Drug Monographs)

(Source: RxList – New and Updated Drug Monographs)

(Source: Drug and Alcohol Dependence)

Updated Date: Jun 13, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))